ProfileGDS5678 / 1453286_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 69% 74% 78% 72% 74% 70% 71% 67% 71% 80% 79% 76% 74% 75% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.2939869
GSM967853U87-EV human glioblastoma xenograft - Control 24.8225674
GSM967854U87-EV human glioblastoma xenograft - Control 35.3267278
GSM967855U87-EV human glioblastoma xenograft - Control 44.7333772
GSM967856U87-EV human glioblastoma xenograft - Control 54.82674
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.3145670
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.4680171
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.0482767
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.4808771
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.6517580
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.5663379
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.1656876
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.8290974
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.9933975